Markets & Regulations

Lilly invests heavily in UK

Lilly invests heavily in UK

US pharmaceutical major Eli Lilly has earmarked a hefty £220
million (€304 million) investment over the next four years in its
UK facilities, representing the largest investment by the firm in
any European country.

FDA panel mulls cGMP issues

FDA panel mulls cGMP issues

As this edition of In-pharmatechnologist.com goes online, the US
Food and Drug Administration is convening the inaugural meeting of
its Advisory Committee for Pharmaceutical Science's Manufacturing
Subcommittee.

New formulation faces the sun

New formulation faces the sun

Speciality chemicals company International Specialty Products (ISP)
continues its quest to expand the company's presence in the growing
personal care market segment with the news this week that it has
collaborated with biotech...

Extending plant powders

Extending plant powders

In the US this week, supplier of botanical extracts for the
pharmaceutical industry Pharmachem Laboratories announced that it
has acquired 'the largest botanical extraction facility in North
America, producing extracts for the...

Biopharma merger in UK

Biopharma merger in UK

Spotlight on the home of the celebrated pork pie in England, with
the annoucement this week that Melton Mowbray-based Bridgehead
Technologies and Pharmalicensing - two biopharmaceutical business
development companies - are to merge.

D&E to offer outsourcing

D&E to offer outsourcing

US manufacturer of vitamins, minerals, herbs and supplements
D&E Pharmaceuticals, has launched a contract manufacturing
services initiative, principally aimed at small to medium sized
nutraceutical suppliers.

Cost cutting at Axis-Shield

Cost cutting at Axis-Shield

In a bid to improve efficiency and reduce costs UK in vitro
diagnostics company Axis-Shield is to shift the manufacture of
certain products from its site in Oslo, Norway to the company's
global headquarters in Dundee, Scotland.